386 related articles for article (PubMed ID: 31289360)
1. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma.
Green NH; Galvan DL; Badal SS; Chang BH; LeBleu VS; Long J; Jonasch E; Danesh FR
Oncogene; 2019 Aug; 38(34):6211-6225. PubMed ID: 31289360
[TBL] [Abstract][Full Text] [Related]
2. MTHFD2 Overexpression Predicts Poor Prognosis in Renal Cell Carcinoma and is Associated with Cell Proliferation and Vimentin-Modulated Migration and Invasion.
Lin H; Huang B; Wang H; Liu X; Hong Y; Qiu S; Zheng J
Cell Physiol Biochem; 2018; 51(2):991-1000. PubMed ID: 30466107
[TBL] [Abstract][Full Text] [Related]
3. Folate enzyme MTHFD2 links one-carbon metabolism to unfolded protein response in glioblastoma.
Zhu Z; Kiang KM; Li N; Liu J; Zhang P; Jin L; He X; Zhang S; Leung GK
Cancer Lett; 2022 Nov; 549():215903. PubMed ID: 36089117
[TBL] [Abstract][Full Text] [Related]
4. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
5. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Shang M; Yang H; Yang R; Chen T; Fu Y; Li Y; Fang X; Zhang K; Zhang J; Li H; Cao X; Gu J; Xiao J; Zhang Q; Liu X; Yu Q; Wang T
Nat Commun; 2021 Mar; 12(1):1940. PubMed ID: 33782411
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of MTHFD2 inhibits NSCLC progression by suppressing cycle-related genes.
Yu C; Yang L; Cai M; Zhou F; Xiao S; Li Y; Wan T; Cheng D; Wang L; Zhao C; Huang X
J Cell Mol Med; 2020 Jan; 24(2):1568-1577. PubMed ID: 31778025
[TBL] [Abstract][Full Text] [Related]
7. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Zhang C; Chen L; Liu Y; Huang J; Liu A; Xu Y; Shen Y; He H; Xu D
Theranostics; 2021; 11(8):3676-3693. PubMed ID: 33664855
[No Abstract] [Full Text] [Related]
8. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin inhibits SIRT3-deacetylation MTHFD2 to disturb cellular redox balance in colorectal cancer cell.
Wan X; Wang C; Huang Z; Zhou D; Xiang S; Qi Q; Chen X; Arbely E; Liu CY; Du P; Yu W
Cell Death Dis; 2020 Aug; 11(8):649. PubMed ID: 32811824
[TBL] [Abstract][Full Text] [Related]
10. Cancer stem-like properties and gefitinib resistance are dependent on purine synthetic metabolism mediated by the mitochondrial enzyme MTHFD2.
Nishimura T; Nakata A; Chen X; Nishi K; Meguro-Horike M; Sasaki S; Kita K; Horike SI; Saitoh K; Kato K; Igarashi K; Murayama T; Kohno S; Takahashi C; Mukaida N; Yano S; Soga T; Tojo A; Gotoh N
Oncogene; 2019 Apr; 38(14):2464-2481. PubMed ID: 30532069
[TBL] [Abstract][Full Text] [Related]
11. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
12. Suppression of MTHFD2 in MCF-7 Breast Cancer Cells Increases Glycolysis, Dependency on Exogenous Glycine, and Sensitivity to Folate Depletion.
Koufaris C; Gallage S; Yang T; Lau CH; Valbuena GN; Keun HC
J Proteome Res; 2016 Aug; 15(8):2618-25. PubMed ID: 27315223
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-33a-5p suppresses colorectal cancer cell growth by inhibiting MTHFD2.
Yan Y; Zhang D; Lei T; Zhao C; Han J; Cui J; Wang Y
Clin Exp Pharmacol Physiol; 2019 Oct; 46(10):928-936. PubMed ID: 31209892
[TBL] [Abstract][Full Text] [Related]
14. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1.
Liu T; Wang H; Fu Z; Wang Z; Wang J; Gan X; Wang A; Wang L
Cancer Sci; 2022 Feb; 113(2):446-458. PubMed ID: 34813676
[TBL] [Abstract][Full Text] [Related]
15. Non-metabolic function of MTHFD2 activates CDK2 in bladder cancer.
Liu X; Liu S; Piao C; Zhang Z; Zhang X; Jiang Y; Kong C
Cancer Sci; 2021 Dec; 112(12):4909-4919. PubMed ID: 34632667
[TBL] [Abstract][Full Text] [Related]
16. MTHFD2-mediated redox homeostasis promotes gastric cancer progression under hypoxic conditions.
Mo HY; Wang RB; Ma MY; Zhang Y; Li XY; Wen WR; Han Y; Tian T
Redox Rep; 2024 Dec; 29(1):2345455. PubMed ID: 38723197
[TBL] [Abstract][Full Text] [Related]
17. MTHFD2 promotes tumorigenesis and metastasis in lung adenocarcinoma by regulating AKT/GSK-3β/β-catenin signalling.
Shi Y; Xu Y; Yao J; Yan C; Su H; Zhang X; Chen E; Ying K
J Cell Mol Med; 2021 Jul; 25(14):7013-7027. PubMed ID: 34121323
[TBL] [Abstract][Full Text] [Related]
18. Suppression of mitochondrial respiration with auraptene inhibits the progression of renal cell carcinoma: involvement of HIF-1α degradation.
Jang Y; Han J; Kim SJ; Kim J; Lee MJ; Jeong S; Ryu MJ; Seo KS; Choi SY; Shong M; Lim K; Heo JY; Kweon GR
Oncotarget; 2015 Nov; 6(35):38127-38. PubMed ID: 26474388
[TBL] [Abstract][Full Text] [Related]
19. The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.
Wang J; Zhang P; Zhong J; Tan M; Ge J; Tao L; Li Y; Zhu Y; Wu L; Qiu J; Tong X
Oncotarget; 2016 May; 7(19):27142-57. PubMed ID: 27049827
[TBL] [Abstract][Full Text] [Related]
20. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage.
Li G; Wu J; Li L; Jiang P
Proc Natl Acad Sci U S A; 2021 Jul; 118(28):. PubMed ID: 34244426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
